Bayer had one patents in advanced materials during Q1 2024. Bayer AG’s patent filed in Q1 2024 describes an intrauterine delivery system combining NSAID and progestogenic compounds, with the anti-inflammatory compound in the frame material and the progestogenic compound in a silicon-based reservoir. The invention also involves creating drug-containing T-intrauterine systems using 3D printing techniques, specifically fused deposition modeling, with different drug contents of Indomethacin in poly-caprolactone-based filaments. GlobalData’s report on Bayer gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Bayer had no grants in advanced materials as a theme in Q1 2024.
Recent Patents
Application: Drug delivery system comprising a non-steroidal anti-inflammatory (NSAID) and a progestogenic compound and methods for manufacturing (Patent ID: US20240009116A1)
The invention by Bayer AG describes an intrauterine delivery system that combines a non-steroidal anti-inflammatory drug (NSAID) and a progestogenic compound. The system involves incorporating the anti-inflammatory active compound into the frame material and containing the progestogenic compound in a silicon-based reservoir attached to the frame, with the frame made of a thermoplastic material. Additionally, the invention aims to create drug-containing T-intrauterine systems (IUS) by utilizing 3D printing techniques, specifically fused deposition modeling (FDM™), to incorporate the drug throughout the entire backbone of the medical device.
The method for manufacturing the frame as part of the intrauterine delivery system involves 3D printing a mixture of a thermoplastic material and an NSAID to create the frame, with a silicone-based reservoir containing a progestogenic compound attached to the frame. The process includes extruding the mixture to form a filament, loading it into a 3D printer, and printing the filament to produce the frame. The filament composition includes ethylene-vinyl acetate copolymer with 16% vinyl acetate content as the thermoplastic material and 5-40 wt % indomethacin as the NSAID. The 3D printing is carried out below the melting point of the NSAID, above the melting point of the thermoplastic material, or both, to ensure proper fabrication of the frame for controlled release of the progestogenic compound required for contraception over an extended period.
To know more about GlobalData’s detailed insights on Bayer, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
